Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Teva corporate bond deal could become year’s 3rd biggest

Teva Pharmaceutical Industries Ltd. is heading towards one of the year’s largest US corporate bond deals as foreign investors stampeded for a piece of the high-quality paper
Teva corporate bond deal could become year’s 3rd biggest
Teva corporate bond sale heavily over-subscribed

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is heading towards one of the year’s largest US corporate bond deals as foreign investors stampeded for a piece of the high quality paper.

The Israeli group, which will use the proceeds to fund its acquisition of Allergan’s (NYSE:AGN) generic drug business, counted orders of $70bn for a bond sale of between $14bn and $16bn.

If completed at the high end of expectations, the transaction would rank as the year’s third-largest corporate bond deal, behind a $46bn sale by Anheuser-Busch InBev and a $20bn offering from computer maker Dell (NASDAQ:DELL).

Teva’s ADRs were changing hands at $52.04, down 0.32%, on Monday.

View full TEVA profile View Profile

Teva Pharmaceutical Industries Timeline

Related Articles

woman at a microscope
September 04 2017
Lead product Lojuxta generated revenues of €5.75mln in the first-half
GW_Pharma.png
June 07 2017
Midatech has three lead R&D programmes: a carcinoid syndrome treatment; a liver cancer drug; and a brain cancer therapy

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use